Market Cap 229.17M
Revenue (ttm) 0.00
Net Income (ttm) -248.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,076,500
Avg Vol 1,012,824
Day's Range N/A - N/A
Shares Out 100.95M
Stochastic %K 52%
Beta 1.07
Analysts Strong Sell
Price Target $8.00

Company Profile

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California. As of May 21, 2025, Acelyrin, Inc. o...

Industry: Biotechnology
Sector: Healthcare
Phone: 805 456 4393
Address:
4149 Liberty Canyon Road, Agoura Hills, United States
tradingcalendar
tradingcalendar May. 21 at 1:25 PM
M&A Acelyric Inc $SLRN merger with and into Alumis $ALMS - Shareholders of SLRN received 0.4814 shares of ALMS for every 1 share of SLRN owned More Information : https://www.sec.gov/ix?doc=/Archives/edgar/data/1962918/000119312525122468/d105874d8k.htm
0 · Reply
G101SPM
G101SPM May. 21 at 1:17 PM
$ALMS $4.88 bid. *DAC $3.80 (5.13.25). EXIT $15.00 (long term) FACT: Alumis has completed its merger with ACELYRIN, Inc. ($SLRN) note: Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned. ACELYRIN common stock has ceased trading and will no longer be listed on the NASDAQ Global Select Market. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.
0 · Reply
OnlyFibs
OnlyFibs May. 21 at 1:05 AM
$SLRN - today had the most 8hr buy volume in 2 months, a move is coming, looking to claim $2.28 to see $2.40, gl! #hovdid
1 · Reply
TwongStocks
TwongStocks May. 20 at 8:34 PM
$SLRN Equity Corporate Actions Alert #2025 - 254 Information Regarding the Merger of ACELYRIN, Inc. (SLRN) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-254 SLRN expected to halt at 7:50pm ET tonight. Merger closing May 21, SLRN suspended effective May 22. "At a special meeting held on May 19, 2025, the shareholders of ACELYRIN, Inc. (SLRN) approved the proposed merger with and into Alumis Inc (ALMS). The merger is tentatively scheduled to close prior to the market open on May 21, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on May 20, 2025. If the merger closes as anticipated, the stock will remain halted on the day of closing (May 21st) and will be suspended effective May 22, 2025."
0 · Reply
iSmith
iSmith May. 16 at 7:16 PM
$VXRT $SLRN With a combined cash position of approximately $737 million — including $289 million from Alumis and $448 million from Acelyrin — Acelyrin said the merger should provide enough runway through multiple planned key data readouts into 2027. Post-merger, Alumis shareholders will own about 52% of the combined company, with Acelyrin shareholders holding the remaining 48%. Current price for ALMS is $5.65, and accordingly, the price for SLRN should be $5.65x0.4814 = $2.72. But it's $2.25... $0.50 free money for current buyers
1 · Reply
iSmith
iSmith May. 15 at 6:45 PM
$SLRN above $2.50 tomorrow
0 · Reply
iSmith
iSmith May. 15 at 6:12 PM
$SLRN Under the amended agreement, Acelyrin shareholders will receive 0.4814 of an Alumis common share for each Acelyrin common share held, according to the statement. The companies said this represents a "meaningful increase" over the initial agreement. ALMS currently at $5.40, and SLRN's current price should be $2.60, but you can buy it right now for $2.15
0 · Reply
G101SPM
G101SPM May. 13 at 5:09 PM
$ALMS $4.83 bid. *DAC (dollar average cost based on $SLRN merger) $3.80. EXIT $15.00. note: Alumis stockholders approve merger with ACELYRIN (SLRN), expected to close in the second quarter of 2025. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.
0 · Reply
10xby3
10xby3 May. 13 at 12:37 PM
$ALMS todays the day - free cash coming from $SLRN and market cap should move towards $700MIL ($7 per share post integration of additional shares).
0 · Reply
Mergerbrief
Mergerbrief May. 13 at 12:14 PM
$SLRN / $ALMS – Shareholder Vote $ALMS, $SLRN Sign Up For full Sched
0 · Reply
Latest News on SLRN
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

Mar 13, 2025, 7:00 AM EDT - 3 months ago

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan


Acelyrin, Inc. (SLRN) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 9:38 PM EST - 8 months ago

Acelyrin, Inc. (SLRN) Q3 2024 Earnings Call Transcript


ACELYRIN, INC. to Participate in Upcoming Investor Conferences

Aug 22, 2024, 7:00 AM EDT - 11 months ago

ACELYRIN, INC. to Participate in Upcoming Investor Conferences


Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep

Aug 14, 2024, 12:29 PM EDT - 11 months ago

Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep


Acelyrin, Inc. (SLRN) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 10:32 PM EDT - 11 months ago

Acelyrin, Inc. (SLRN) Q2 2024 Earnings Call Transcript


ACELYRIN INVESTOR DEADLINE APPROACHING

Jan 11, 2024, 1:30 PM EST - 1 year ago

ACELYRIN INVESTOR DEADLINE APPROACHING


ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors

Dec 20, 2023, 4:30 PM EST - 1 year ago

ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors


Acelyrin Looks Interesting Before PsA Data In Q1

Dec 7, 2023, 8:00 AM EST - 1 year ago

Acelyrin Looks Interesting Before PsA Data In Q1


tradingcalendar
tradingcalendar May. 21 at 1:25 PM
M&A Acelyric Inc $SLRN merger with and into Alumis $ALMS - Shareholders of SLRN received 0.4814 shares of ALMS for every 1 share of SLRN owned More Information : https://www.sec.gov/ix?doc=/Archives/edgar/data/1962918/000119312525122468/d105874d8k.htm
0 · Reply
G101SPM
G101SPM May. 21 at 1:17 PM
$ALMS $4.88 bid. *DAC $3.80 (5.13.25). EXIT $15.00 (long term) FACT: Alumis has completed its merger with ACELYRIN, Inc. ($SLRN) note: Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned. ACELYRIN common stock has ceased trading and will no longer be listed on the NASDAQ Global Select Market. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.
0 · Reply
OnlyFibs
OnlyFibs May. 21 at 1:05 AM
$SLRN - today had the most 8hr buy volume in 2 months, a move is coming, looking to claim $2.28 to see $2.40, gl! #hovdid
1 · Reply
TwongStocks
TwongStocks May. 20 at 8:34 PM
$SLRN Equity Corporate Actions Alert #2025 - 254 Information Regarding the Merger of ACELYRIN, Inc. (SLRN) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-254 SLRN expected to halt at 7:50pm ET tonight. Merger closing May 21, SLRN suspended effective May 22. "At a special meeting held on May 19, 2025, the shareholders of ACELYRIN, Inc. (SLRN) approved the proposed merger with and into Alumis Inc (ALMS). The merger is tentatively scheduled to close prior to the market open on May 21, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on May 20, 2025. If the merger closes as anticipated, the stock will remain halted on the day of closing (May 21st) and will be suspended effective May 22, 2025."
0 · Reply
iSmith
iSmith May. 16 at 7:16 PM
$VXRT $SLRN With a combined cash position of approximately $737 million — including $289 million from Alumis and $448 million from Acelyrin — Acelyrin said the merger should provide enough runway through multiple planned key data readouts into 2027. Post-merger, Alumis shareholders will own about 52% of the combined company, with Acelyrin shareholders holding the remaining 48%. Current price for ALMS is $5.65, and accordingly, the price for SLRN should be $5.65x0.4814 = $2.72. But it's $2.25... $0.50 free money for current buyers
1 · Reply
iSmith
iSmith May. 15 at 6:45 PM
$SLRN above $2.50 tomorrow
0 · Reply
iSmith
iSmith May. 15 at 6:12 PM
$SLRN Under the amended agreement, Acelyrin shareholders will receive 0.4814 of an Alumis common share for each Acelyrin common share held, according to the statement. The companies said this represents a "meaningful increase" over the initial agreement. ALMS currently at $5.40, and SLRN's current price should be $2.60, but you can buy it right now for $2.15
0 · Reply
G101SPM
G101SPM May. 13 at 5:09 PM
$ALMS $4.83 bid. *DAC (dollar average cost based on $SLRN merger) $3.80. EXIT $15.00. note: Alumis stockholders approve merger with ACELYRIN (SLRN), expected to close in the second quarter of 2025. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.
0 · Reply
10xby3
10xby3 May. 13 at 12:37 PM
$ALMS todays the day - free cash coming from $SLRN and market cap should move towards $700MIL ($7 per share post integration of additional shares).
0 · Reply
Mergerbrief
Mergerbrief May. 13 at 12:14 PM
$SLRN / $ALMS – Shareholder Vote $ALMS, $SLRN Sign Up For full Sched
0 · Reply
JL_TradeZ
JL_TradeZ May. 11 at 4:58 AM
After dropping a bunch of setups today, figured I’d narrow it down to what I’m personally watching the closest. Top setups I’d prioritize based on early entry, clean chart, low float, and real breakout potential: • $AMPG – Micro float + AI/NASA angle. Tight setup and feels ready to go with volume. • $CXAI – Coiled and curling. Perfect base forming under breakout. AI bounce could send this flying. • $MSGM – Gaming + low float. Sitting under 2.50 trigger. Could squeeze fast. • $BOXL – Say what you want, but the setup’s clean. If 1.60 breaks, this can rip. • $SLRN – Under the radar, but one of the strongest. $2.5-3+ All of these match my criteria—low float, no dilution risk, real catalyst angles, and serious upside. If you’ve been following my plays lately, you already know I don’t just post to post—I break it down with structure, early entries, and real catalysts. Smash that like if this helped—and drop any tickers you want me to scan next. Let’s build something that actually lasts.
0 · Reply
Stocksavior14
Stocksavior14 May. 11 at 3:04 AM
$BOXL $CXAI $QUBT $SGLY $SLRN BOXL $2??🤣 what’s the reasoning behind it?
1 · Reply
JL_TradeZ
JL_TradeZ May. 10 at 9:13 PM
Weekend Watchlist $CXAI — Current: $1.05 • Breakout: $1.20 • Entry: $0.95–1.03 • Risk: Below $0.92 • Targets: $1.30 / $1.50+ • Catalyst: AI bounce + past runner potential $BOXL — Current: $1.50 • Breakout: $1.60 • Entry: $1.35–1.45 • Risk: Below $1.30 • Targets: $1.75 / $2.00 • Catalyst: Micro float + edtech news could trigger $SGLY — Current: $1.14 • Breakout: $1.25 • Entry: $1.05–1.12 • Risk: Below $1.00 • Targets: $1.40 / $1.60+ • Catalyst: China sympathy + security tech angle $QUBT — Current: $8.57 • Breakout: $9.00 • Entry: $8.30–8.50 • Risk: Below $8.00 • Targets: $9.80 / $10.50 • Catalyst: Quantum hype + AI crossover sector $SLRN — Current: $2.36 • Breakout: $2.50 • Entry: $2.30–2.45 • Risk: Below $2.25 • Targets: $2.80 / $3.10 / $3.50 • Catalyst: May 13 merger vote + $737M cash runway. Every setup here has breakout potential and a reason behind it. No fluff—just structure and timing. Smash that like if you’re locked in for next week.
1 · Reply
JL_TradeZ
JL_TradeZ May. 10 at 9:00 PM
$SLRN Watch for a clean break over $2.50 If that confirms with volume, targets are: • $2.80 / $3.10 / $3.50+ (short-term stretch level) Entry: $2.30–$2.45 Risk: Under $2.25 (tight stop) Setting up for a breakout. It’s not guaranteed—but once the catalyst + timing + clean chart come together, this could easily push for a 100–200% move once everything drops 🤫
0 · Reply
JL_TradeZ
JL_TradeZ May. 10 at 8:55 PM
$SLRN Keep an eye on this one. The merger vote is scheduled for this coming Monday, and this is still early. Closed at $2.36 on Friday. Float’s around 101M, but the setup is what matters here. Acelyrin is merging with Alumis, and the vote is locked in for May 13. If it passes, the combined company walks away with a $737M cash runway and a late-stage biotech pipeline targeting serious immunology diseases. Analyst targets hit as high as $20, and there’s no dilution risk on deck. MACD is curling, RSI’s sitting in the 40s, and the chart is coiling tight just under $2.50. Merger press release: https://investors.alumis.com/news-releases/news-release-details/alumis-and-acelyrin-announce-amended-merger-agreement SEC filing confirming merger terms: https://www.sec.gov/Archives/edgar/data/1962918/000119312525086274/d849091dex992.htm $20 analyst target: https://www.tipranks.com/stocks/slrn/forecast
0 · Reply
Armonica423
Armonica423 May. 10 at 6:09 PM
$SLRN Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research
0 · Reply
EquityInvest
EquityInvest May. 5 at 5:08 AM
$SLRN yet another hopeless stock founded by a so-called scientist from China. Has anyone ever heard of a house of cards ha ha
0 · Reply
RollingDollars
RollingDollars May. 1 at 2:01 PM
0 · Reply
RollingDollars
RollingDollars May. 1 at 2:01 PM
0 · Reply
RollingDollars
RollingDollars Apr. 29 at 7:22 PM
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Apr. 21 at 10:43 AM
$SLRN shareholders to own 48% of combined entity post-merger with Alumis. Revised exchange ratio at 0.4814 Alumis shares per ACELYRIN share. Both boards unanimously - deal closes May 19. Speculative play hinges entirely on pipeline success. Current cash position ($73.9M) raises eyebrows given burn rate. https://www.sec.gov/Archives/edgar/data/1962918/000119312525086274/d849091d8k.htm
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Apr. 21 at 10:32 AM
Alumis ($ALMS) revises merger terms with ACELYRIN ($SLRN), boosting SLRN holders to 48% ownership in combined entity. $737M cash runway to 2027 aims to advance late-stage immunology pipeline. Strategic play, but dilution questions remain ahead of May 13 shareholder votes. https://www.sec.gov/Archives/edgar/data/1847367/000110465925036483/tm2512707d4_8k.htm
1 · Reply